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Abstract: Rab GTPases are implicated in endosome-to-plasma membrane recycling, but 
how such membrane traffic regulators control vascular endothelial growth factor receptor 2 
(VEGFR2/KDR) dynamics and function are not well understood. Here, we evaluated two 
different recycling Rab GTPases, Rab4a and Rab11a, in regulating endothelial VEGFR2 
trafficking and signalling with implications for endothelial cell migration, proliferation and 
angiogenesis. In primary endothelial cells, VEGFR2 displays co-localisation with Rab4a, 
but not Rab11a GTPase, on early endosomes. Expression of a guanosine diphosphate 
(GDP)-bound Rab4a S22N mutant caused increased VEGFR2 accumulation in endosomes. 
TfR and VEGFR2 exhibited differences in endosome-to-plasma membrane recycling in the 
presence of chloroquine. Depletion of Rab4a, but not Rab11a, levels stimulated VEGF-A-
dependent intracellular signalling. However, depletion of either Rab4a or Rab11a levels 
inhibited VEGF-A-stimulated endothelial cell migration. Interestingly, depletion of Rab4a 
levels stimulated VEGF-A-regulated endothelial cell proliferation. Rab4a and Rab11a were 
also both required for endothelial tubulogenesis. Evaluation of a transgenic zebrafish model 
showed that both Rab4 and Rab11a are functionally required for blood vessel formation and 
animal viability. Rab-dependent endosome-to-plasma membrane recycling of VEGFR2 is 
important for intracellular signalling, cell migration and proliferation during angiogenesis. 
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Abbreviations: EEA1: early endosome antigen 1; EGFR: epidermal growth factor receptor; eNOS: 
endothelial nitric oxide synthase; ERK: extracellular signal-regulated kinase; ESCRT: endosomal 
sorting complex required for transport; FACS: fluorescence-activated cell sorting; GDP: guanosine 
diphosphate; GTP: guanosine triphosphate; HUVEC: human umbilical vein endothelial cell; PLC: 
phospholipase C; VEGF-A: vascular endothelial growth factor A; VEGFR: vascular endothelial 
growth factor receptor. 
1. Introduction 
Membrane receptor recycling is an important function in regulating animal physiology [1–3]. 
Although the machinery controlling recycling from intracellular endosomes has not been fully 
characterised, endosome-associated Ras-related (Rab) GTPases are implicated in regulating such 
pathways [4]. Two such Rab GTPases, Rab4a and Rab11a, regulate different recycling routes from 
early endosomes back to the plasma membrane [5]. In endothelial cells, Rab4a is functionally involved 
in membrane protein recycling from endosomes, exemplified by vascular endothelial growth factor 
receptors (VEGFRs) and αVβ3 integrin [5]. A Rab-independent and c-Src-dependent pathway has 
been postulated to regulate recycling from endosome-to-plasma membrane in endothelial cells [6]. 
The vascular endothelial growth factor (VEGF) family of cytokines plays essential roles in 
vasculogenesis, angiogenesis and animal physiology [2,7,8]. Vascular endothelial growth factor A 
(VEGF-A) is the most well-characterized family member. Different splice variants exist with  
VEGF-A165 (termed VEGF-A) being the most abundant and well-studied family member [9]. Loss of a 
single VEGF-A allele impairs vascular development and causes embryonic lethality, emphasizing the 
functional importance of VEGF-A in animal physiology [10,11]. VEGF-A can bind to two receptor 
tyrosine kinases (RTKs), i.e., either fms-like tyrosine kinase (VEGFR1 or Flt-1) or kinase insert 
domain receptor (VEGFR2 or KDR). VEGF-A binding to RTKs can also recruit membrane  
co-receptors, called neuropilins (NRP1, NRP2). VEGF-A-stimulated VEGFR2 activation in 
endothelial cells triggers multiple signal transduction steps, such as extracellular signal-regulated 
kinase (ERK1/2), the serine/threonine protein kinase Akt (PKB) and endothelial nitric oxide synthase 
(eNOS) inter alia [7]. Such pro-angiogenic signal transduction cascades regulates endothelial 
functions ranging from cell survival, proliferation, migration, tubulogenesis and angiogenesis  
to vasculogenesis [8]. 
VEGFR2-regulated signal transduction events have been intensively studied, but how this is  
coordinated with receptor trafficking and vascular physiology is poorly understood. Whilst endocytosis 
of RTKs can attenuate signalling events, such outputs can differ, dependent on the location within the 
endocytic pathway [12–14]. Activated RTKs usually have two possible fates: recycling back to the 
plasma membrane or degradation within the endosome-lysosome pathway. At steady state, quiescent 
VEGFR2 is localised to both the plasma membrane and early endosomes [6,12,15]; ligand-stimulated 
activation causes VEGFR2 trans-autophosphorylation, ubiquitination, endosome and lysosome-linked 
proteolysis [14]. Both quiescent and activated VEGFR2 can be recycled [6,15], but how this is 
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balanced with lysosomal delivery for proteolysis is not understood. Here, we test a role for Rab 
GTPases that regulate different endosome-to-plasma membrane routes. These studies reveal that 
VEGFR2 exhibits unique dependence on Rab4a and Rab11a activity in controlling endothelial 
function, vascular development and physiology. 
2. Experimental Section 
2.1. Materials, Cell Culture, Microscopy and Flow Cytometry 
Recombinant human VEGF-A165 was a gift from Genentech Inc. (San Francisco, CA, USA). 
Isolation and culture of primary human umbilical vein endothelial cells (HUVECs) was described 
previously [16]. Purified goat anti-VEGFR2 extracellular domain (R&D Systems, Abingdon, UK) and 
mouse monoclonal anti-Rab4a antibodies (BD Biosciences, Oxford, UK) were used with horseradiah 
peroxidase (HRP)-conjugated secondary antibodies (ThermoFisher, Loughborough, UK) and 
AlexaFluor-conjugated secondary antibodies (Invitrogen, Amsterdam, Netherlands). Non-endothelial 
cell culture medium and supplements were from Invitrogen (Paisley, UK), whereas endothelial cell 
growth medium and supplements were from Promocell (Heidelberg, Germany). HUVECs were fixed 
and processed for immunofluorescence microscopy, as described previously [16,17]. All other reagents 
were purchased from Sigma-Aldrich (Poole, UK), unless otherwise stated.  
For flow cytometry [17], HUVECs were treated as appropriate, and medium was removed from 
cells and kept on ice. Cells were trypsinized and resuspended in original media. Cells were rinsed in 
ice-cold phosphate-buffered saline (PBS) and fixed in 3% paraformaldehyde for 20 min. After washes 
in blocking buffer (1 mg/mL bovine serum albumin (BSA) in PBS), cells were incubated with goat 
anti-VEGFR2 (10 μg/mL) for 30 min, washed three times and then incubated with rabbit anti-goat 
AlexaFluor488 conjugate (10 μg/mL) for 30 min. Cells were washed twice more in binding buffer 
followed by the addition of 2 mg/mL of 4',6'-diamidino-2-phenylindole (DAPI) prior to analysis using 
a Fortessa flow cytometer (Beckton Dickinson, U.K.). Cells labelled with DAPI alone were used as 
controls to set up appropriate gating parameters. 
Cycloheximide (CHX) was routinely used to inhibit new protein synthesis and deplete Golgi and 
ER-associated VEGFR2 and monitor only the plasma membrane and endosomal pools of VEGFR2. 
CHX (50 μg/mL) was used for 2 h during the VEGF-A stimulation period before fixation or cell lysis 
for further analysis. 
2.2. Gene Manipulation and RNA Interference 
Cells were transfected with GFP-tagged human Rab4a (Francis Barr, University of Oxford, UK), 
human Rab5a (Brian Knoll, University of Texas, USA) or canine Rab11a (Nigel Bunnett, Monash 
University, Australia) wild-type or mutant proteins, as previously described [17]. HUVECs were 
transfected with siRNA duplexes using Lipofectamine 2000 as specified (Invitrogen, Amsterdam, 
Holland). Cells were assayed 48 h following transfection. siRNA duplexes targeting human Rab4a and 
Rab11a were designed, synthesized and annealed. RNA interference (RNAi) targeting Rab4a had a 
sense sequence of 5' GUUCUUGGUUAUUGGAAAU 3'. Non-targeting control siRNA duplex 
(Silencer Negative Control #1; Ambion, Warrington, U.K.) was also used.  
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2.3. Intracellular Signalling Analysis 
HUVEC lysate preparation and immunoblotting were performed as described previously [12,14,17]. 
Briefly, confluent HUVEC monolayers were lysed in 2% (w/v) SDS in PBS and the lysate subsequently 
boiled for 5 min at 95 °C. Proteins were separated by SDS-PAGE on 10% gels and then transferred onto 
nitrocellulose membranes. The following antibodies were used: anti-VEGFR2 extracellular domain 
(R&D Systems, Minneapolis, USA), anti-Akt, anti-phospho-Akt (pS473), anti-ERK1/2,  
anti-phospho-ERK1/2, anti-phospho-VEGFR2 (pY1175), anti-phospho-p38 (Cell Signaling 
Technology, Danvers, USA), anti-Rab4a, anti-Rab11a and anti-α-tubulin (Santa Cruz Biotechnology, 
Santa Cruz, USA). Immunoreactive bands were visualized using an enhanced chemiluminescence 
detection kit (Geneflow, Nottingham, U.K.). Antibodies to α-tubulin were used as internal controls in 
immunoblot experiments. 
2.4. Cell Migration, Proliferation and Tubulogenesis Assays 
Endothelial cell migration assays were carried out as described previously [17–19]. Control or 
siRNA-treated confluent HUVEC monolayers were trypsinised and seeded at 5 × 104 cells/mL into a 
24-well plate with 8-µm pore size Transwell inserts (BD Biosciences, Oxford, UK). Endothelial cell 
migration was stimulated by VEGF-A (50 ng/mL) in the lower chamber. After 16 h, the Transwell 
units were fixed in 3% paraformaldehyde, stained with hematoxylin-eosin and circular inserts excised 
for microscopy analysis. Digital microscopy images of the underside (containing migratory endothelial 
cells) of each Transwell insert were analysed; random fields from each image dataset were evaluated 
for the percentage (%) of migrated endothelial cells. In the cell proliferation assay [17], endothelial 
cells were subjected to control (scrambled), Rab4a or Rab11a siRNA treatment for the specified 
period, trypsinized and seeded at 1,000 cells per well in 96-well plates and grown for 24 h and 
processed using a 5-bromo-2-deoxyuridine (BrdU) ELISA (Roche Diagnostics, Lewes, UK). An in 
vitro endothelial tubulogenesis assay involved the co-culture of endothelial cells on a primary 
fibroblast monolayer. Endothelial cells were subjected to control (scrambled), Rab4a or Rab11a 
siRNA treatment for the specified period, trypsinised and seeded on a bed of human primary 
fibroblasts in 24-well plates and cultured for 7 days in growth medium containing VEGF-A  
(50 ng/mL). Cells were fixed using paraformaldehyde, stained and imaged by phase contrast microscopy 
as previously described [17]. Tubule length was quantified using Image J (NIH, Bethesda, MD,  
USA) software. 
2.5. Transgenic Zebrafish Manipulation and Analysis 
This was carried out as previously described [20]. Four nanolitres of morpholino (Gene-Tools, 
Philomath, USA) in a 100 μM stock solution were injected into the yolk sac of transgenic Fli1-GFP 
embryos at the 1- to 4-cell stage. In each treatment, ~100 embryos were injected and allowed to 
develop for 48 h. The injected morpholino sequences were: Rab4a: 5' CAAGAAATCGTAT 
GTCTCTGACAT 3'; Rab11a: 5' GTATTCGTCGTCTCGTGTCCCCATC 3'. Pictures of the zebrafish 
embryos were obtained under brightfield using a NikonSMZ1500 optical microscope. Microscopy data 
were acquired using a Leica TCS SP2 confocal microscope (excitation at 488 nm) at a 100× 
Cells 2014, 3 367 
 
 
magnification. To check for Rab knockdown, 100 dechorionated embryos were washed twice in cold 
Ringer’s solution (116 mM NaCl, 2.9 mM KCl, 1.8 mM CaCl2, 5 mM Hepes, pH 7.2), followed by 
mechanical removal of the yolk sac through a thin pipette tip. Embryos were lysed, sonicated in 
lysisuffer (30 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) deoxycholate, 2 mM 
ETDA) and SDS sample buffer added. SDS-PAGE and immunoblotting using primary and HRP 
conjugated secondary antibodies were carried out as previously described. 
2.6. Statistical Analysis 
Datasets and error bars denote the mean ± SEM (standard error of the mean). The statistical 
significance of differences between datasets was analysed using the Student’s t-test, where p < 0.05 
was considered significant. 
3. Results and Discussion 
3.1. VEGFR2 Recycles to the Plasma Membrane via Rab4a-Containing Endosomes 
Previous work has shown that the VEGFR2 exhibits both plasma membrane and endosomal 
localisation [6,12,15,21]. To test whether VEGFR2 undergoes a ligand-independent endosome-to-
plasma membrane recycling step in quiescent primary human endothelial cells, monensin can be used, 
as this agent inhibits cell surface receptor recycling [22–25]. Primary endothelial cells were first 
subjected to a block in new protein synthesis using cycloheximide: we detected a stable and distal pool 
of VEGFR2, which showed partial co-distribution with the transferrin receptor (TfR) present in early 
endosomes (Figure 1A, upper panels). Simultaneous treatment with monensin and cycloheximide for 
30 min increased VEGFR2 co-distribution with TfR in early endosomes (Figure 1A, insets). Following 
simultaneous VEGF-A and cycloheximide treatment, VEGFR2 levels markedly decreased in the 
absence of new protein synthesis (Figure 1B). Monensin further potentiated this VEGF-A-stimulated 
decrease in VEGFR2 levels (Figure 1B). Inhibition of endosome-to-plasma membrane recycling would 
be thus predicted to decrease cell surface VEGFR2 levels. Flow cytometry analysis showed a ~25% 
decrease in cell surface VEGFR2 levels after 30-min exposure to monensin, compared with 
cycloheximide-treated cells, which showed no significant change in VEGFR2 levels (Figure 1C). 
Thus, both quiescent and activated VEGFR2 undergoes endosome-to-plasma membrane recycling. 
Figure 1. Inhibition of endosome-to-plasma membrane recycling restricts VEGFR2 to a 
perinuclear compartment. (A) Human umbilical vein endothelial cells (HUVECs) were  
pre-treated for 2 h with cycloheximide (CHX) prior to treatment with 20 μM monensin for 
zero, 30 or 120 min. Cells were then fixed, permeabilised and labelled with goat anti-VEGFR2 
extracellular domain (green) and mouse anti-TfR (red). Primary antibodies were visualized 
using AlexaFluor-conjugated species-specific secondary antibodies, and the nucleus was 
labelled with DAPI (blue). Bar: 10 μm. Insets show a two-fold magnification of the 
indicated regions. (B) Serum-starved HUVECs were pre-treated with 20 μM monensin 
prior to VEGF-A stimulation for zero, 30 or 120 min. Cell lysates were immunoblotted 
with antibodies specific for VEGFR2 or actin. The data shown is representative of three 
independent experiments. (C) Flow cytometry analysis of HUVECs treated with either 20 μM 
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monensin or 50 μg/mL cycloheximide (CHX) for zero, 30, 60 or 120 min. Error bars 
denote ± SEM (n = 3); *, p < 0.05.  
 
 
Rab GTPases, such as Rab4a or Rab11a, regulate different endosome-to-plasma membrane 
recycling routes [26–32] and are functionally linked to VEGFRs in endothelial cells [6,21,33]. To 
differentiate between these two endosome-linked recycling pathways, we overexpressed GFP-tagged 
wild-type Rab4a or Rab11a in endothelial cells and assessed co-distribution with VEGFR2 using 
quantitative microscopy (Figure 2). Endothelial cell transfection and expression of GFP-Rab4a caused 
the accumulation of punctate structures with Rab4a-enriched membranes and a central core of 
‘trapped’ VEGFR2 within the internal lumen (Figure 2A, upper panels and inset). In contrast, 
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transfection and expression of GFP-Rab11a showed non-overlapping distribution of VEGFR2 and 
Rab11a to different vesicles (Figure 2A, lower panels and inset). Quantification of VEGFR2  
co-distribution of either Rab4a or Rab11a in such experiments revealed a significant difference 
between these two GTPases (Figure 2B). To further assess the link between early endosomes and 
VEGFR2 dynamics, we compared the co-distribution of early endosomal antigen 1 (EEA1),  
GFP-Rab4a and VEGFR2 (Figure 2C). These experiments showed that a proportion of EEA1-positive 
endosomes also contained Rab4a and VEGFR2 (Figure 2C, arrows). 
Figure 2. VEGFR2 trafficking in early endosomes is closely associated with the Rab4a 
GTPase. (A) HUVECs were transfected with either GFP-Rab4a or GFP-Rab11a (green), 
fixed and probed with goat antibodies to the VEGFR2 extracellular domain, followed by 
AlexaFluor-labelled secondary antibodies (red). The nucleus was visualised with DAPI 
(blue). (B) Quantification of VEGFR2 co-localisation with GFP-Rab4a or GFP-Rab11a 
(see Materials and Methods). Error bars denote SEM (n = 45); * p < 0.05. (C) VEGFR2 is 
present in Rab4a-positive early endosomes. HUVECs were transiently transfected to 
express GFP-Rab4a (green), and cells were fixed, permeabilised and labelled with goat 
anti-VEGFR2 (red) and rabbit anti-EEA1 (blue). Bound primary antibodies were visualised 
with AlexaFluor-conjugated secondary antibodies. Insets show a two-fold magnification of 
the highlighted region. Bar: 10 μm. 
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3.2. VEGFR2 Endosome-to-Plasma Membrane Recycling Depends on Rab4a GTPase Activity 
VEGF-A-activated VEGFR2 undergoes ubiquitination and proteolysis within the  
endosome-lysosome system within 2 h, even when new protein synthesis is blocked [12]. To address 
whether Rab4a influences VEGFR2 trafficking and degradation, we analysed VEGF-A-stimulated 
VEGFR2 activation and internalisation in GFP-Rab4a-expressing endothelial cells (Figure 3A–C). 
VEGFR2-positive/Rab4a-positive endosomes were prominent even 2 h after ligand stimulation in the 
presence of cycloheximide to inhibit further protein synthesis (Figure 3C’, insets). This delayed 
VEGFR2 trafficking effect was linked to increased Rab4a expression; and therefore, may be regulated 
by the Rab4a guanosine triphosphate (GTP)/guanosine diphosphate (GDP)-bound state. To test this, 
we overexpressed a GDP-bound dominant-negative Rab4a mutant (GFP-Rab4a-S22N) in endothelial 
cells and evaluated VEGFR2 trafficking and distribution following VEGF-A stimulation using 
microscopy (Figure 3D–F). This GDP-bound Rab4a mutant may be expected to prevent the recycling 
of VEGFR2 and, therefore, enhances the proportion of the receptor pool that is subject to lysosomal 
degradation. GDP-bound Rab4a-S22N localised to a juxtanuclear membrane compartment clearly 
distinct from VEGFR2 localization (Figure 3D). Endothelial cells expressing juxtanuclear  
Rab4a-S22N did not show co-distribution with endosomal VEGFR2; however, in these cells, 
endosomal VEGFR2 levels persisted (Figure 3D’–F’). Interestingly, VEGF-A-stimulation still 
exhibited increased VEGFR2 retention within endosomes and reduced VEGFR2 degradation  
(Figure 3F’) in comparison to control non-transfected cells. 
Different membrane receptors recycle from the endosome-to-plasma membrane via Rab4a- or 
Rab11a-dependent pathways [26,29]. To further test for Rab11a involvement in the regulation of VEGFR2 
endosome-to-plasma membrane recycling, we overexpressed either wild-type or dominant-negative 
(S25N) Rab11a proteins in endothelial cells and stimulated with VEGF-A (Figure 4). Expression of 
GFP-Rab11a in endothelial cells followed by VEGF-A stimulation revealed two findings. Firstly, there 
was little or no co-distribution between VEGFR2 and Rab11a (Figure 4A,B). Secondly, VEGF-A-
stimulated VEGFR2 activation for 2 h caused noticeable VEGFR2 degradation (Figure 4C’) in cells 
overexpressing Rab11a (Figure 4C), thus resembling control non-transfected endothelial cells (see 
Figure 1A). We also overexpressed a GDP-bound dominant-negative Rab11a mutant (GFP-Rab11a-
S25N) and evaluated VEGFR2 trafficking and distribution in transfected endothelial cells (Figure 4D–4F). 
Interestingly, GDP-bound Rab11a-S25N also localised to a juxtanuclear membrane compartment in 
transfected endothelial cells (Figure 4D), and this was distinct from VEGFR2 distribution (Figure 
4D’). In contrast to previous experiments with Rab4a-S22N, Rab11a-S25N expression did not 
significantly affect VEGF-A-stimulated VEGFR2 activation and degradation via the endosome-
lysosome system (Figure 4F’). 
Figure 3. Wild-type and mutant Rab4a-S22N blocks VEGF-A-stimulated VEGFR2 
degradation. (A–C) HUVECs were transfected with GFP-Rab4a (green) and cells were 
then stimulated with VEGF-A for (A) 0 min, (B) 30 min or (C) 120 min in the presence of 
CHX. Cells were subsequently fixed, permeabilised and labelled with goat anti-VEGFR2 
followed by AlexaFluor-conjugated secondary antibody (red). The nucleus is visualized 
using DAPI (blue). Inset panels show a two-fold magnification of boxed highlighted 
regions. Bar: 10 μm. (D–F) HUVECs were transiently transfected to express  
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dominant-negative GDP-bound GFP-Rab4a-S22N (green) and then stimulated with  
VEGF-A for (D) 0 min, € 30 min or (F) 120 min in the presence of cycloheximide (CHX) 
and processed for immunofluorescence microscopy. VEGFR2 was detected using goat 
anti-VEGFR2 followed by AlexaFluor-conjugated secondary antibody (red), whilst the 
nuclear DNA was labelled with DAPI (blue). The images shown are representative of three 
independent experiments. Inset panels show a two-fold magnification of boxed highlighted 
regions. Bar: 10 μm. 
 
Figure 4. Rab11a perturbation does not affect VEGF-A stimulated VEGFR2 degradation. 
(A–C) HUVECs were transiently transfected to express GFP-Rab11a (green) and then 
stimulated with VEGF-A for (A) 0 min, (B) 30 min or (C) 120 min in the presence of 
cycloheximide (CHX) and processed for immunofluorescence microscopy. VEGFR2 was 
detected using goat anti-VEGFR2 antibody followed by AlexaFluor-conjugated secondary 
antibody (red), whilst the nuclear DNA was labelled with DAPI (blue). The images shown 
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are representative of three independent experiments. Inset panels show a two-fold 
magnification of boxed highlighted regions. Bar: 10 μm. (D–F) HUVECs were transiently 
transfected to express dominant-negative GDP-bound GFP-Rab11a-S25N (green) and then 
stimulated with VEGF-A for (D) 0 min, (E) 30 min or (F) 120 min in the presence of 
cycloheximide (CHX) and processed for immunofluorescence microscopy. VEGFR2 was 
detected using goat anti-VEGFR2 followed by AlexaFluor-conjugated secondary antibody 
(red), whilst the nuclear DNA was labelled with DAPI (blue). The images shown are 
representative of three independent experiments. Inset panels show a two-fold 
magnification of boxed highlighted regions. Bar: 10 μm. 
 
3.3. The VEGFR2 and TfR Recycling Pathways Are Distinct and Modulate Signal Transduction 
A number of previous studies have established that VEGFR2 undergoes endosome-to-plasma 
membrane recycling [6,15,21]. We used the previously described antibody-based recycling assay to 
monitor VEGFR2 and TfR recycling [15]. Chloroquine (CHQ) is an inhibitor of endosomal 
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compartment acidification and, therefore, blocks endocytosis [34]. Upon CHQ treatment of endothelial 
cells, both recycling VEGFR2 and TfR accumulated in enlarged endosomal structures (Figure 5). 
Intriguingly, whilst TfR showed a high level of co-localisation with EEA1 (Figure 5A), VEGFR2 
showed little co-localisation with EEA1 under similar conditions (Figure 5B). These data indicate 
differences in VEGFR2 and TfR recycling. Neither VEGFR2 nor TfR showed any co-localisation with 
cathepsin D in the presence of CHQ (Figure 5C and D). 
Figure 5. Chloroquine causes TfR, but not VEGFR2, accumulation in endosomes. A direct 
recycling assay was performed using the goat anti-VEGFR2 extracellular domain or mouse 
anti-TfR (red). Samples were fixed, permeabilised and labelled with either rabbit anti-
EEA1 (green) or rabbit anti-cathepsin D (green). Primary antibodies were visualised using 
either FITC anti-rabbit IgG or AlexaFluor-488-conjugated anti-rabbit IgG, and the nucleus 
was seen with DAPI (blue). The images are 2D projections of a stacked series of 15–30 μm 
optical sections taken using a wide field deconvolution microscopy system. Insets show a 
two-fold magnification of the indicated region. Bar: 10 μm. 
 
Does Rab4a GTPase activity and regulation of endosome-to-plasma membrane recycling influence 
VEGF-A-stimulated intracellular signalling in endothelial cells? We have previously used RNA 
interference (RNAi) to evaluate Rab5a and Rab7a GTPase regulation of VEGFR2 function linked to 
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endosome-lysosome trafficking and VEGF-A-stimulated intracellular signalling in primary endothelial 
cells [17]. We used this approach to check whether Rab4a or Rab11a depletion modulated VEGF-A-
stimulated short-term intracellular signalling, therefore altering longer term cellular responses, such as 
endothelial cell migration, proliferation and endothelial tube formation, i.e., tubulogenesis.  
Analysis of VEGF-A-stimulated VEGFR2 activation revealed subtle differences in VEGFR2 
activation and downstream signal transduction (Figure 6A). Quantification showed a nearly two-fold 
increase in VEGFR2-pY1175 levels upon Rab11a depletion, whereas Rab4a depletion did not 
significantly affect VEGFR2-pY1175 levels (Figure 6B). Furthermore, VEGF-A-stimulated Akt 
activation was prolonged upon Rab4a depletion compared to controls and Rab11a-depleted cells, 
although peak phospho-Akt levels were not significantly altered (Figure 6C). However, the effects on 
p42/44 MAPK (ERK1/2) activation were less pronounced (Figure 6D). Rab4a or Rab11a depletion did 
not affect peak phospho-p42/44 MAPK levels, but the duration of this species was prolonged (Figure 
6D). Similarly, although Rab4a and Rab11a depletion did not affect peak levels of VEGF-A-stimulated 
intracellular signalling and activation of endothelial nitric oxide synthase (eNOS), the duration of the 
activated phospho-eNOS (peNOS) species was also prolonged; an affect more pronounced upon 
Rab11a depletion (Figure 6E). The activation of p38 MAPK was unaffected by the depletion of either 
Rab4a or Rab11a.  
Figure 6. Effects of Rab silencing on VEGF-A-stimulated intracellular signalling in 
endothelial cells. (A) HUVECs were subjected to RNAi (see Materials and Methods) and 
the control; Rab4a- or Rab11a-depleted HUVECs were then stimulated with VEGF-A 
followed by quantitative immunoblotting for (B) VEGFR2-pY1175, (C) phosphorylated 
Akt (p-Akt S473), (D) phosphorylated MAPK (p42/44 MAPK or p-ERK1/2 T202/Y204) 
and (E) phosphorylated eNOS (p-eNOS S1179). The data shown are derived from the 
analysis of three or more independent experiments. Error bars denote ±SEM, with asterisks 
indicating significance (*, p < 0.05). 
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Figure 6. Cont. 
 
3.4. Rab GTPase Regulation of Intracellular Signalling Cell Migration, Proliferation  
and Tubulogenesis 
To test if altered Rab-dependent VEGFR2 recycling influences VEGF-A responses, we analysed 
endothelial cell migration in Rab4a or Rab11a-depleted endothelial cells (Figure 7A). Endothelial cells 
subjected to Rab4a knockdown showed ~20% reduction in cell migration in VEGF-A-supplemented 
minimal medium compared to complete medium (Figure 7A). In cells subjected to Rab11a knockdown, 
cell migration was reduced ~20% in complete media and reduced ~40% in VEGF-A-supplemented 
minimal media (Figure 7A). To assess such effects for another physiological response, such as VEGF-
A-stimulated cell proliferation, endothelial cells subjected to Rab4a knockdown showed nearly a three-
fold increase in cell proliferation relative to controls (Figure 7B). In contrast, Rab11a-depleted 
endothelial cells did not show altered cell proliferation (Figure 7B). In the absence of VEGF-A or 
adequate medium for >6–12 h, there is pronounced endothelial necrosis/apoptosis that is further 
accentuated by siRNA treatments. To control for this aspect, we used comparisons with scrambled 
siRNA controls (control siRNA) and other Rab-specific siRNAs as described here. 
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Next, we used an organotypic endothelial-fibroblast co-culture assay to recapitulate the endothelial 
tube formation characteristic of VEGF-A-stimulated angiogenesis. We analysed endothelial 
tubulogenesis in Rab4a or Rab11a-depleted endothelial cells subjected to sustained VEGF-A treatment 
for seven days (Figure 7C). Endothelial cells showed ~50% reduction in the incidence of branch points 
in tubular networks upon depletion of either Rab4a or Rab11a GTPase (Figure 7C and D). 
Interestingly, VEGF-A-stimulated endothelial tubule length was only reduced by ~10%  
in Rab4a-depleted cells; whilst there was a ~30% decrease in tubule length in Rab11a-depleted cells 
(Figure 7E). These findings suggested key differences in the mechanism of Rab GTPase action on 
VEGFR2 recycling linked to long-term cellular responses. 
Figure 7. Rab-mediated regulation of endothelial cell migration, proliferation and in vitro 
angiogenesis. HUVECs were subjected to RNAi (see Materials and Methods) and the 
control; Rab4a- or Rab11a-depleted HUVECs were then analysed for (A) cell migration 
using a Transwell assay in complete media, VEGF-A-supplemented minimal media or in 
minimal media alone, (B) endothelial cell proliferation using a 5-bromo-2-deoxyuridine 
(BrdU)-modified nucleotide DNA incorporation ELISA or (C) endothelial tubule formation 
(tubulogenesis) using an organotypic endothelial-fibroblast co-culture assay. RNAi-activated 
HUVECs were trypsinized and plated on a bed of confluent human fibroblasts and allowed 
to grow in the presence of excess VEGF-A for seven days before endothelial tubules 
became visible. Co-cultures were fixed, stained with anti-PECAM-1 (CD31) antibody and 
HRP-conjugated secondary antibody followed by processing for light microscopy. 
Endothelial tubules were then analysed for (D) the number of branch points and (E) the 
total tubule length after tubulogenesis using Image J software. Error bars denote ±SEM;  
*, p < 0.05; **, p < 0.01. 
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Figure 7. Cont. 
 
To address whether Rab4a and Rab11a activity is important for blood vessel growth and 
angiogenesis in vivo, morpholino-mediated knockdown of these Rab GTPases was carried out in 
transgenic Fli1-GFP zebrafish embryos, where GFP expression is restricted to vascular endothelium in 
the developing embryo [20,35]. Control scrambled, Rab4a- or Rab11a-specific morpholino antisense 
oligonucleotides were used to target Rab4a or Rab11a gene expression, and vascular development was 
analysed (Figure 8).  
Figure 8. Rab4a regulates vascular development in transgenic zebrafish. Fluorescence 
microscopy on representative (A) control, (B) Rab4a-depleted or (C) Rab11a-depleted 
zebrafish transgenic lines (morphants) expressing Fli1:EGFP. Arrows in panel B denote 
defects in blood vessel formation in Rab4a-depleted animals. (D) Immunoblotting of 
control, Rab4a- or Rab11a-depleted transgenic zebrafish extracts. 
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In controls (Figure 8A), a well-defined vascular system was evident with intersegmental vessels 
(ISV) connecting the major dorsal aorta and dorsal longitudinal anastomotic vessel (DLAV). Specific 
morpholino oligonucleotide-mediated Rab4a depletion (Rab4a morphants) caused severe impairment 
of both ISV and DLAV formation, with ISVs often missing or prematurely terminated (Figure 8B). In 
contrast, although Rab11a morphants displayed marked developmental defects (Figure 8C), including 
some disruption to the embryonic vasculature, both ISV and DLAV appeared to be better preserved 
than in Rab4a morphants (Figure 8C). Immunoblotting revealed substantial knockdown in protein 
levels of either Rab4a or Rab11a using specific morpholino antisense oligonucleotides (Figure 8D). 
Zebrafish morphology upon depletion of either Rab4a or Rab11a also revealed pleiotropic 
morphological effects, higher developmental abnormalities and mortalities in comparison to controls 
(S.P. et al., unpublished findings). 
3.5. Discussion 
Here, we provide evidence that a Rab GTPase-dependent endosome-to-plasma membrane recycling 
step regulates VEGF-A-dependent intracellular signalling, cell migration, proliferation and 
angiogenesis. VEGFR2 recycles in both the presence and absence of VEGF-A stimulation. The Rab4a 
and Rab11a GTPases exhibited differential effects on VEGF-A-stimulated cell proliferation and 
migration. Rab4a depletion caused a dramatic three-fold increase in the VEGF-A-dependent 
proliferative response. However, Rab11a depletion did not affect endothelial cell proliferation. Rab4a 
displayed a modest reduction in VEGF-A-stimulated cell migration, whilst Rab11a depletion affected 
cell migration mediated by both serum and VEGF-A. A VEGF-A-dependent model of endothelial 
tubulogenesis showed a requirement for both Rab4a and Rab11a, but regulation by both GTPases 
appeared more crucial for tubule branching rather than extension of tubule length. This observation 
could in part explain the discrepancy between increased cell proliferation and decreased cell migration 
in Rab4a-depleted endothelial cells. Rab4a or Rab11a depletion in a transgenic zebrafish model 
produced different effects on vascular development, indicating the involvement in VEGF-A-regulated 
processes. However, it is also possible that such effects on animal development are not directly related 
to VEGF-VEGFR2 function, but rather, are a consequence of the essential roles of such GTPases in 
trafficking and the function of other membrane receptors. 
Overexpression of Rab4a and Rab11a wild-type, or mutant GTPases, indicated a role for Rab4a in 
VEGFR2 trafficking from early endosomes to the plasma membrane. Comparison of VEGFR2 
trafficking upon overexpression of a constitutively active GTP-bound Rab4a-Q67L mutant (S.P. et al., 
unpublished findings) showed that different Rab4a mutants can cause a block in activated VEGFR2 
trafficking through the endosome-lysosome system. Depletion of Rab4a did not significantly affect 
VEGFR2 levels or phosphorylation status, although downstream activation of Akt, a serine/threonine 
protein kinase and master regulator, was prolonged. In contrast, Rab11a depletion did not affect Akt 
activation. Depletion of Rab4a also perturbed activated VEGFR2 proteolysis, consistent with the 
requirement for VEGFR2 recycling from early endosome to the plasma membrane following ligand 
stimulation. Thus, a link exists between endosomal Rab4a and the VEGF-A-dependent response in the 
endothelium. However, it cannot be discounted that other components of signalling pathways (e.g., 
MAPK enzymes, PDK1, Akt) that localise to the endocytic pathway may also be disrupted by Rab 
depletion, thus also modulating VEGF-A-stimulated responses. 
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It has been previously shown that VEGFR2 undergoes recycling from endosomes to the plasma 
membrane [6,15,21]. However, Mellor and colleagues postulated that although VEGFR2 showed  
co-distribution with Rab4a-positive endosomes, they argued that VEGFR2 recycles from peripheral 
endosomes via a Src-dependent pathway [6]. Ballmer-Hofer and colleagues showed that VEGFR2 
recycling via Rab4a- or Rab11a-regulated pathways is dependent on VEGFR2 association with  
NRP1 [21]. We had previously employed both biochemical and microscopy-based assays to show that 
VEGFR2 does indeed recycle between the cell surface and endosomes, and this was dependent on 
VEGFR2 tyrosine kinase activity [15]. This study suggests that Rab4a, but not Rab11a, is required for 
VEGFR2 recycling. This is at variance with previous findings [21]. However, we do observe 
significant differences between TfR and VEGFR2 recycling, suggesting that the two receptors share 
common regulatory features (e.g., Rab4a), but also differences in trafficking from endosomes to the 
plasma membrane.  
The localisation of VEGFR2 along the endocytic pathways is regulated by different GTPases [2,3]. 
Our previous work showed that Rab5a regulated VEGFR2 trafficking through early endosomes [36]. 
VEGFR2 early endosome localization was associated with pro-angiogenic signalling from early 
endosomes, including ERK1/2 activation and cell migration. However, although Rab7a regulated 
VEGFR2 trafficking out of late endosomes, retention in this compartment decreased pro-angiogenic 
signal transduction [36]. These findings suggest that quiescent VEGFR2 is efficiently recycled back to 
the cell surface via Rab4a-positive endosomes; however, this recycling may also occur through 
Rab11a-positive endosomes, depending on the association with NRP1 [21]. However, if VEGFR2 
undergoes activation, phosphorylation and ubiquitination and these post-translational modifications are 
not removed in the early endosome, activated VEGFR2 progresses towards late endosomes and 
eventual degradation in lysosomes; compartments that are positioned close to the nucleus [37]. 
The different effects noted for unchanged VEGFR2 phosphorylation status versus prolonged Akt 
activation following Rab4a depletion represents a possible differential spatio-temporal regulation of 
these signalling molecules. A mutant Rab4a does not prevent internalisation of VEGFR2 from the 
plasma membrane (where phosphorylation is initiated), suggesting that such downstream signalling 
events may be initiated in internal membrane compartments, a phenomenon which has been previously 
suggested [13,14]. A VEGFR1- and Rab4a-dependent step is also implicated in regulating endothelial 
αVβ3 integrin recycling and the pro-angiogenic response [38]. Inhibition or depletion of endocytic 
regulators, including clathrin, ESCRT or Rab proteins, can also affect VEGFR2 trafficking, processing 
and downstream signalling [12,14,36]. Expression of dominant-negative Rab4a in epithelial cells also 
inhibits ligand-stimulated degradation of another receptor tyrosine kinase, EGFR/ErbB1 [39].  
VEGFR2 undergoes constitutive endocytosis, but displays a lower internalisation rate than the 
constitutively endocytosed transferrin receptor (~8% per min); this is still a relatively high level of 
constitutive endocytosis (S.P. et al., unpublished observations). VEGFR2 can localise to both the 
plasma membrane and intracellular vesicles in endothelial cells. A large fraction of VEGFR2 resides 
within early endosomes, whilst the remaining fraction is present at the plasma membrane, concordant 
with previous studies. VEGFR2-mediated cellular outputs have been observed to be linked to lipid 
rafts and associated factors, which can also modulate signal transduction, trafficking and recycling in 
other pathways [40–44]. Increased VEGFR2 endocytosis triggered by VEGF-A could be linked to 
VEGFR2 exit from plasma membrane caveolae or lipid rafts to facilitate receptor-mediated 
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endocytosis. Although plasma membrane VEGFR2 internalisation increased ~1.5-fold upon VEGF-A 
stimulation (S.P. et al., unpublished observations), this does not account for increased endosome-to-
plasma membrane recycling. Inhibition of endosome-to-plasma membrane recycling using the 
ionophore, monensin, in quiescent cells resulted in the accumulation of VEGFR2 in a perinuclear 
compartment and a decrease in plasma membrane VEGFR2, when new protein synthesis was also 
inhibited. This suggests that VEGFR2 is continually recycling through the endosome-plasma 
membrane system, even in the absence of the VEGF-A ligand. 
In contrast to VEGFR2, other transmembrane receptor kinases, such as TGF-β receptor Type I and 
Type II transmembrane proteins, undergo endocytosis, but recycle via a Rab11a-dependent  
pathway [45,46]. Rab11a GTPase activity is also implicated in regulating β2-adrenergic receptor 
recycling and degradation [32]. However, other G-protein coupled receptors appear to differentially 
utilize Rab4a and Rab11a recycling pathways for recycling [25,47]. A comparison of two different 
prostaglandin G-protein-coupled receptors also suggests differential use of Rab4a versus Rab11a recycling 
pathways [47]. There is also likely to be some overlap between these two routes, as transferrin receptor 
endosome-plasma membrane recycling is dependent on both Rab4a and Rab11a. One possibility is that 
membrane proteins are segregated into ‘fast’ or ‘slow’ recycling routes from endosomes depending on 
the physiological context. 
4. Conclusions  
Members of the Rab family of small GTPases, such as Rab4a and Rab11a, are notable regulators of 
receptor recycling from endosomes [5,48]. Early and recycling endosomes resemble membrane 
mosaics containing different regulatory proteins, including Rab GTPases [29,30,49]. Divalent Rab 
effector proteins further regulate the specificity of protein-protein and protein-lipid interactions within 
these specialized membrane domains [30]. Interestingly, the dependence of VEGFR2 recycling on 
Rab4a has similarities to the GLUT4 glucose transporter, which is stored in intracellular vesicles and 
undergoes insulin- and Rab4a-dependent trafficking to the plasma membrane [50–54]. Rab4a regulates 
the rapid recycling pathway of the transferrin receptor [26,55] and a G-protein-coupled receptor, 
cannabinoid receptor CB1 [56]. In contrast, Rab11a is located to perinuclear recycling endosomes and 
regulates a secondary slow recycling pathway for the transferrin receptor [27–30] and other  
G-protein-coupled receptors [25,47,57–59]. Our studies have thus demonstrated an essential role for 
endosome-to-plasma membrane recycling dependence on Rab GTPases. Although Rab4a shows the 
most involvement in VEGFR2 trafficking and regulation of the pro-angiogenic response, Rab11a 
appears to also have subtle effects. Our findings thus also suggest that these closely related pathways 
are highly interlinked, and membrane flux changes in one pathway likely affect the other, with 
differing consequences for animal physiology. 
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